Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
Sponsor: NeuroTrauma Sciences, LLC
Summary
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
Official title: A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Domain Within the ACT-GLOBAL Trial Platform, to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
Key Details
Gender
All
Age Range
45 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-10-31
Completion Date
2028-12-15
Last Updated
2026-08-03
Healthy Volunteers
No
Conditions
Interventions
NTS-521
Intravenous NTS-521
Placebo Control
0.9% saline solution delivered intravenously